ABSTRACT
Objective Predict long-term disease worsening and the removal of biosimilar medication in patients with rheumatic diseases.
Methodology Observational, retrospective descriptive study. Review of a database of patients with immune-mediated inflammatory rheumatic diseases who switched from a biological drug (biosimilar or non-biosimilar) to a biosimilar drug for at least 6 months. We selected the most important variables, from 18 variables, using mutual information tests. As patients with disease worsening are a minority, it is very difficult to make models with conventional machine learning techniques, where the best models would always be trivial. For this reason, we computed different types of imbalanced machine learning models, choosing those with better f1-score and mean ROC AUC.
Results We computed the best-imbalanced machine learning models to predict disease worsening and the removal of the biosimilar, with f1-scores of 0.52 and 0.63, respectively. Both models are decision trees. In the first one, two important factors are switching of biosimilar and age, and in the second, the relevant variables are optimization and the value of the initial PCR.
Conclusions Biosimilar drugs do not always work well for rheumatic diseases. We obtain two imbalanced machine learning models to detect those cases, where the drug should be removed or where the activity of the disease increases from low to high. In our decision trees appear not previously studied variables, such as age, switching, or optimization.
Key points
- This is a real-life study of a large number of patients with biosimilar bDMARDs.
- Biosimilar drugs can be considered effective in rheumatic inflammatory diseases, as measured by ASDAS, DAPSA and DAS28.
- The bDMARDs biosimilars are safe drugs with a low number of side effects.
- After switching from the reference drug to a biosimilar drug, patients have a high withdrawal rate due to ineffectiveness.
- Our machine learning model (imbalanced machine learning) is able to predict when drug withdrawal and disease activity occur.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We have a document with the final approval of the Clinical Research Ethics Committee of the General University Hospital of Ciudad Real, approved on October 25, 2022 (act 10/2022, C-567) and all methods were performed in accordance with the relevant guidelines and regulations. In addition, we have obtained the patient's written informed consent to participating in the study and to publish the material.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
